Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Spain / NCT05688592
Recruiting Observational

Usefulness of PET-CT for Invasive Fungal Infection

NCT05688592 · tracked via the Priya Life Science Spain tracker
Sponsor
Puerta de Hierro University Hospital
Phase
Observational
Started
2023-04-27
Last updated
2024-11-06

Condition(s) studied

Invasive Fungal Infections

Investigational drug(s) / intervention(s)

PET-CT

PET-CT: This is a before-and-after study (not a clinical trial) * in the case of fungemia, 2 weeks after the initial staging 18F-FDG PET-CT. * in the case of focal IFIs, 2-4 and 12 weeks after the initial staging 18F-FDG PET-CT

Study summary

The goal of this national multicenter prospective cohort study is to learn about the added value of 18F-FDG (18F-2-fluoro-2-deoxy-D-glucose) PET-CT in invasive fungal disease management. The main questions it aims to answer are:

1. Does the use of 18F-FDG PET-CT allow a better characterization of invasive fungal infection (IFI) (performance) compared to the exclusive use of conventional radiological studies in terms of extension/staging and monitoring of response/follow-up ?
2. Does the systematic and protocolized use of 18F-FDG PET-CT in IFI allow a better management of patients with IFI and increase the prognostic value of the initial evaluation? Participants will undergo systematically a 18F-FDG PET-CT as part of the work-up of their invasive fungal disease. Researchers will compare the performance of 18F-FDG PET-CT with standard management without 18F-FDG PET-CT to see if adds value (diagnostic, prognostic, and changes in management).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion criteria: * 18-year-old adult patients * who are admitted with a diagnosis of invasive fungal infection * who able to undergo a one 18F-FDG PET-CT * who give their informed consent. Exclusion criteria: * concomitant active bacterial infection likely to produce uptake in organs and tissues * recent surgery in the area of the IFI (in the previous 3 months) * other medical conditions that interfere with the development of the study ( e.g., inability to tolerate the performance of the test during the required time, pregnancy) * terminal situation.

Primary outcome measure(s)

Trial sites (14)

FacilityCityRegionStatus
Hospital Universitario Puerta de Hierro Majadahonda Madriid Recruiting
Hospital de Bellvitge Barcelona Spain Recruiting
Hospital Universitario Clinic Barcelona Spain Recruiting
Hospital Universitario Virgen de las Nieves Granada Spain Recruiting
Hospital Infanta Leonor Hospital Madrid Spain Recruiting
Hospital Universitario Gregorio Marañón Madrid Spain Recruiting
Hospital Universitario La Paz Madrid Spain Recruiting
Hospital Unversitario Ramón y Cajal Madrid Spain Recruiting
Hospital Virgen de la Victoria Málaga Spain Recruiting
Hospital Morales Messeguer Murcia Spain Not Yet Recruiting
Hospital Virgen de la Arrixaca Murcia Spain Not Yet Recruiting
Hospital Universitario Central de Asturias Oviedo Spain Recruiting
Hospital Unversitario de Salamanca Salamanca Spain Recruiting
Hospital Universitario Virgenn de la Macarena Seville Spain Recruiting

More Puerta de Hierro University Hospital trials in Spain

Laparoscopic Gastric Bypass Versus Laparoscopic Banded Gastric Bypass Randomized Prospective Clinical Trial Enrolling by invitation
Effect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction Starting soon
REACTION-VAD Trial: Remote Exercise Training Via Telemedicine in Patients With Long-Term Ventricular Assist Devices Starting soon
Impact of Cardiac Rehabilitation Adapted for Patients With Heart Failure Starting soon
Heart Failure Patient Management and Interventions Using Continuous Patient Monitoring Outside Hospitals and Real-world Data Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05688592 on ClinicalTrials.gov ↗ ← All trials in Spain